Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
March 18 2014 - 9:00AM
Marketwired
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker:
SNGX); $5.50 Price Target
SAN FRANCISCO, CA--(Marketwired - Mar 18, 2014) - Vista Partners
announced today that it has initiated coverage on Soligenix, Inc.
(OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix,
Inc. is a New Jersey based clinical stage biopharmaceutical company
committed to developing products to treat life-threatening side
effects of cancer treatments and serious gastrointestinal diseases.
Ross Silver, Principal Analyst at Vista Partners, stated,
"Soligenix has signed an exclusive worldwide collaboration deal
with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a
novel passive immunotherapy for Melioidosis. Melioidosis, also
known as Bp, is an often deadly infectious disease caused by the
bacterium, Burkholderia pseudomallei, with some symptoms similar to
those of the flu and pneumonia. Melioidosis occurs in many
different places around the globe, currently however it is of
greatest concern in southeast-Asia and northern Australia, where
public officials see it as a major threat to the health of the
population." Mr. Silver continues, "The Company also has an
exclusive commercial collaboration with SciClone Pharmaceuticals
($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment
of oral mucositis." Mr. Silver concludes, "The Company boasts a
diverse pipeline with nine prospective drug candidates. The science
behind the Company's prospective therapies has been and continues
to be validated by a number of significant, important and
influential entities such as government organizations and major
pharmaceutical companies. To date the Company has been awarded
approximately $40M mainly through BARDA, NIH and FDA
grants/contracts. The Company has up to approximately $34 million
in active government contract and grant funding still available to
support its associated research programs through 2018."
To download a FREE copy of the Soligenix, Inc. research report,
please visit http://www.vistapglobal.com and click the "download
research" icon to gain access to the report.
About Vista
Partners: Vista Partners LLC, founded in 2005, is a
Registered Investment Advisor in the States of California and
Oregon. The firm's professional staff has backgrounds in finance,
corporate communications and investment banking. Vista focuses on
investing globally across all market sectors. Vista also provides
investment considerations on publicly traded companies through a
platform of stock research reports, newsletters, company specific
webpages and daily commentary. The platform of products is meant to
serve as potential tools for investors to learn about investment
considerations. It is Vista's mission to provide investors with
tools that may enable them to make profitable investment decisions
with the goal to deliver investment considerations that outperform
small, mid and large cap equity indexes.
Please follow us on Twitter @VistaPResearch & Facebook at
Vista-Partners to receive updates, thoughts and ideas about and our
coverage universe of companies and more.
Disclaimer & Disclosure: For a full list of disclaimers and
disclosures, please visit our website www.vistapglobal.com or click
here.
Contact: Vista Partners 877.215.4813 Email Contact
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Apr 2024 to May 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From May 2023 to May 2024